{"id":"W2626225244","doi":"10.1212/wnl.0000000000004313","title":"Alemtuzumab CARE-MS I 5-year follow-up","year":2017,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":223,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Montreal Neurological Institute and Hospital","funders":"EMD Serono; University of Cambridge; Genentech; Grifols; Multiple Sclerosis Society; Sanofi Genzyme; Five Prime Therapeutics; Acorda Therapeutics; Canadian Institutes of Health Research; GW Pharmaceuticals; Multiple Sclerosis Society of Canada; Eli Lilly and Company; CSL Behring; GlaxoSmithKline; Biogen; Bayer HealthCare; Sanofi; Teva Pharmaceutical Industries","keywords":"Alemtuzumab; Medicine; Expanded Disability Status Scale; Adverse effect; Internal medicine; Clinical endpoint; Discontinuation; Pediatrics; Randomized controlled trial; Multiple sclerosis; Psychiatry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002462667,0.0004588547,0.001243911,0.0005824935,0.0005737356,0.0005721168,0.0004401256,0.0005801279,0.002152309],"category_scores_gemma":[0.002304926,0.0001207799,0.0008102823,0.0004666094,0.0001900734,0.0005538049,0.0004173967,0.000855758,0.0006794445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007731877,"about_ca_system_score_gemma":0.0006393678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00135926,"about_ca_topic_score_gemma":0.001609674,"domain_scores_codex":[0.9992006,0.0001526889,0.0001003503,0.0001885399,0.0001889041,0.0001688981],"domain_scores_gemma":[0.9982201,0.0001639356,0.0007841297,0.0001027502,0.0004225083,0.0003064698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08047228,0.004346746,0.6281022,0.001006746,0.00305705,0.0007307346,0.0003352637,0.002701645,0.01211721,0.0003416425,0.01097813,0.2558103],"study_design_scores_gemma":[0.00526896,0.06054388,0.9063038,0.0002231128,0.0030373,0.001405951,0.00007826427,0.001965646,0.005857055,0.0002642417,0.0149952,0.00005671881],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9691886,0.009564945,0.001589875,0.0002861056,0.00009957892,0.0009023415,0.007311434,0.0003033722,0.01075385],"genre_scores_gemma":[0.9875593,0.0008112667,0.0007597415,0.0005512918,0.00008469271,0.0003606162,0.008184358,0.0000110913,0.001677743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002462667,"threshold_uncertainty_score":0.01302397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0569578367612932,"score_gpt":0.3447063250614835,"score_spread":0.2877484883001903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}